Agenus Inc. (Nasdaq: AGEN) today announced that it is has entered into a non-exclusive license agreement with VaxLogic, LLC, a subsidiary of PharmLogic LLC, for the use of QS-21 Stimulon® 1  adjuvant in the development of select addiction, allergy and respiratory disease vaccine candidates.

Agenus Inc. (Nasdaq: AGEN) today announced the closing of its previously announced agreement to sell $10 million of shares of its common stock, together with warrants to purchase additional shares of its common stock, in a registered direct offering to institutional investors.

Agenus Inc. (Nasdaq: AGEN) today announced the closing of its previously announced agreement to sell $10 million of shares of its common stock, together with warrants to purchase additional shares of its common stock, in a registered direct offering to institutional investors.

Agenus Inc. (Nasdaq: AGEN) today announced that it has received commitments from institutional investors to purchase an aggregate of approximately $6.5 million of its common stock at the market. Agenus entered into a definitive purchase agreement with these investors pursuant to which it agreed to

Agenus Inc. (Nasdaq: AGEN) today announced that Dr. Garo Armen, chairman and CEO of Agenus, will participate in a webcast, titled "Glioblastoma – Brain Cancer: The Next Generation of Therapies," being sponsored by ProActive Capital Group on Monday, September 23, 2013 at 12 noon ET.

Analysis of patients treated with Prophage Series G-100 (HSPPC-96) show improvement in progression free survival and overall survival versus standard of care Results support advancement to Phase 3 trial for HSPPC-96 Agenus Inc. (Nasdaq: AGEN) today announced that a recent analysis from a Phase 2

In Line with Independent Data Monitoring Committee’s (IDMC) Unanimous Recommendation, GSK will Continue Study Until Second Co-primary Endpoint is Assessed Agenus Inc. (Nasdaq: AGEN) today announced that GlaxoSmithKline’s (NYSE: GSK) DERMA i  study, a Phase 3 randomized, blinded, placebo-controlled

Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will present a corporate overview at two upcoming conferences. Dr. Garo Armen, chairman and CEO of Agenus, will present at the 15th Annual Rodman & Renshaw Healthcare

Agenus to Host Conference Call Beginning at 11 a.m. ET Today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (Nasdaq: AGEN ), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its financial results and business

Agenus Inc. (NASDAQ: AGEN) will release its second quarter 2013 financial results before the market opens on July 25, 2013. Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the live call, dial 647-426-1845.

Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the JMP Securities 8th Annual Healthcare Conference, which will be held at the St. Regis New York. Dr.

Agenus Inc. (NASDAQ: AGEN) invites investors and the general public to its Annual Shareholders’ Meeting at 5:00 p.m. ET on Wednesday, June 12, 2013. The meeting will be held at the company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m.

Study seeking to enroll 222 patients; largest vaccine trial ever funded by NCI in brain tumors and the largest cancer vaccine study ever conducted in combination with Avastin Agenus Inc. (NASDAQ: AGEN) today announced enrollment has started for a large, randomized Phase 2 study of Prophage G-200

Agenus to Host Conference Call Beginning at 11 a.m. ET Today Agenus Inc. (Nasdaq: AGEN ), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its financial results and business highlights for the first quarter ended March

Agenus Inc. (Nasdaq:AGEN) will release its first quarter 2013 financial results before the market opens on April 24, 2013. Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the live call, dial 647-426-1845; the access code is  R128039 .

First Phase 2 Data From Prophage G-100 (HSPPC-96) Newly Diagnosed Glioma Program Agenus Inc. (NASDAQ: AGEN) reported today that Orin Bloch, MD, Clinical Instructor, Department of Neurological Surgery, University of California San Francisco (UCSF), will present an abstract that reports on outcomes

Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 25 th  Annual ROTH Conference, which will be held at the Ritz Carlton, Laguna Nigel in Dana Point, California. Jonae R.

Agenus to Host Conference Call Beginning at 11 a.m. ET Today Agenus Inc. (Nasdaq: AGEN ), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its financial results and business highlights for the fourth quarter and year

HerpV is clinically the most advanced therapeutic vaccine for the treatment of genital herpes HerpV contains Agenus’ QS-21 Stimulon®* adjuvant currently being studied in 17 other clinical programs Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases,

Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the Cowen and Company 33 rd  Annual Healthcare Conference, which will be held at the Boston Marriott Copley Place Hotel. Dr.

Agenus Inc. (NASDAQ: AGEN) will release its fourth quarter and year ended December 31, 2012 financial results before the market opens on February 28, 2013. Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the live call, dial 877.475.3568 (domestic)